Oral Corticosteroids for Teprotumumab-Related Hearing Loss: A Case Report

Teprotumumab is a novel insulin-like growth factor-1 receptor inhibitor approved for the treatment of thyroid eye disease, but growing reports of hearing loss require further investigation. To date, an effective protocol for managing hearing loss in this setting has not been determined. Here, we pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Tracy J., Amarikwa, Linus, Winn, Bryan J., Inserra, Michelle, Dosiou, Chrysoula, Kossler, Andrea L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10074260/
https://www.ncbi.nlm.nih.gov/pubmed/37034380
http://dx.doi.org/10.1159/000529422

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10074260/
https://www.ncbi.nlm.nih.gov/pubmed/37034380
http://dx.doi.org/10.1159/000529422

Ejemplares similares